Efficacy of an alpha-blocker for the treatment of nonneurogenic voiding dysfunction in women: An 8-week, randomized, double-blind, placebo-controlled trial

Young Suk Lee, Kyu Sung Lee, Myung Soo Choo, Joon Chul Kim, Jeong Gu Lee, Ju Tae Seo, Jeong Zoo Lee, Ji Youl Lee, Seung June Oh, Yong Gil Na

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: To evaluate the efficacy of an alpha-1 adrenergic receptor (α1-AR) blocker for the treatment of female voiding dysfunction (FVD) through a pressure-flow study. Methods: This was a randomized, double-blind, placebo-controlled trial. Women aged ≥18 years with voiding symptoms, as defined by an American Urological Association symptom score (AUA-SS) ≥15 and a maximum flow rate (Qmax) <15 mL/ sec with a voided volume of >100 mL and/or a postvoid residual (PVR) volume >150 mL, were randomly allocated to either the alfuzosin or placebo group. After 8 weeks of treatment, changes in the AUA-SS, Bristol female lower urinary tract symptoms (BFLUTS) questionnaire, Qmax/PVR, and voiding diary were compared between groups. Patients' satisfaction with the treatment was compared. Patients were categorized into 3 groups according to the Blaivas-Groutz bladder outlet obstruction (BOO) nomogram: none, mild, and moderate to severe. Subgroup comparisons were also made. Results: Of a total of 187 women, 154 (79 alfuzosin, 75 placebo) were included in the analysis. After 8 weeks of treatment, the AUA-SS decreased by 7.0 in the alfuzosin group and by 8.0 in the placebo group. Changes in AUA-SS subscores, BFLUTS (except the I-sum), the voiding diary, and Qmax/PVR were not significantly different between groups. Approximately 54% of the alfuzosin group and 62% of the placebo group were satisfied with the treatment. No significant difference was observed between groups according to the presence or grade of BOO. Conclusions: Alfuzosin might not be more effective than placebo for treating FVD. The presence or the grade of BOO did not affect the results. A further study with sufficient power is needed to determine the efficacy of α1-AR blockers for the treatment of FVD.

Original languageEnglish
Pages (from-to)30-40
Number of pages11
JournalInternational Neurourology Journal
Volume22
Issue number1
DOIs
Publication statusPublished - 2018 Mar 1

Fingerprint

Placebos
Urinary Bladder Neck Obstruction
Lower Urinary Tract Symptoms
Adrenergic alpha-1 Receptor Antagonists
Therapeutics
Nomograms
Residual Volume
Adrenergic Antagonists
Patient Satisfaction
Adrenergic Receptors
alfuzosin
Pressure

Keywords

  • Adrenergic alpha-antagonists
  • Bladder outlet obstruction
  • Female
  • Urodynamics

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Urology

Cite this

Efficacy of an alpha-blocker for the treatment of nonneurogenic voiding dysfunction in women : An 8-week, randomized, double-blind, placebo-controlled trial. / Lee, Young Suk; Lee, Kyu Sung; Choo, Myung Soo; Kim, Joon Chul; Lee, Jeong Gu; Seo, Ju Tae; Lee, Jeong Zoo; Lee, Ji Youl; Oh, Seung June; Na, Yong Gil.

In: International Neurourology Journal, Vol. 22, No. 1, 01.03.2018, p. 30-40.

Research output: Contribution to journalArticle

Lee, Young Suk ; Lee, Kyu Sung ; Choo, Myung Soo ; Kim, Joon Chul ; Lee, Jeong Gu ; Seo, Ju Tae ; Lee, Jeong Zoo ; Lee, Ji Youl ; Oh, Seung June ; Na, Yong Gil. / Efficacy of an alpha-blocker for the treatment of nonneurogenic voiding dysfunction in women : An 8-week, randomized, double-blind, placebo-controlled trial. In: International Neurourology Journal. 2018 ; Vol. 22, No. 1. pp. 30-40.
@article{927b5c726433431493042e53cc22df27,
title = "Efficacy of an alpha-blocker for the treatment of nonneurogenic voiding dysfunction in women: An 8-week, randomized, double-blind, placebo-controlled trial",
abstract = "Purpose: To evaluate the efficacy of an alpha-1 adrenergic receptor (α1-AR) blocker for the treatment of female voiding dysfunction (FVD) through a pressure-flow study. Methods: This was a randomized, double-blind, placebo-controlled trial. Women aged ≥18 years with voiding symptoms, as defined by an American Urological Association symptom score (AUA-SS) ≥15 and a maximum flow rate (Qmax) <15 mL/ sec with a voided volume of >100 mL and/or a postvoid residual (PVR) volume >150 mL, were randomly allocated to either the alfuzosin or placebo group. After 8 weeks of treatment, changes in the AUA-SS, Bristol female lower urinary tract symptoms (BFLUTS) questionnaire, Qmax/PVR, and voiding diary were compared between groups. Patients' satisfaction with the treatment was compared. Patients were categorized into 3 groups according to the Blaivas-Groutz bladder outlet obstruction (BOO) nomogram: none, mild, and moderate to severe. Subgroup comparisons were also made. Results: Of a total of 187 women, 154 (79 alfuzosin, 75 placebo) were included in the analysis. After 8 weeks of treatment, the AUA-SS decreased by 7.0 in the alfuzosin group and by 8.0 in the placebo group. Changes in AUA-SS subscores, BFLUTS (except the I-sum), the voiding diary, and Qmax/PVR were not significantly different between groups. Approximately 54{\%} of the alfuzosin group and 62{\%} of the placebo group were satisfied with the treatment. No significant difference was observed between groups according to the presence or grade of BOO. Conclusions: Alfuzosin might not be more effective than placebo for treating FVD. The presence or the grade of BOO did not affect the results. A further study with sufficient power is needed to determine the efficacy of α1-AR blockers for the treatment of FVD.",
keywords = "Adrenergic alpha-antagonists, Bladder outlet obstruction, Female, Urodynamics",
author = "Lee, {Young Suk} and Lee, {Kyu Sung} and Choo, {Myung Soo} and Kim, {Joon Chul} and Lee, {Jeong Gu} and Seo, {Ju Tae} and Lee, {Jeong Zoo} and Lee, {Ji Youl} and Oh, {Seung June} and Na, {Yong Gil}",
year = "2018",
month = "3",
day = "1",
doi = "10.5213/inj.1834904.452",
language = "English",
volume = "22",
pages = "30--40",
journal = "International Neurourology Journal",
issn = "2093-4777",
publisher = "Korean Association of Medical Journal Edirors",
number = "1",

}

TY - JOUR

T1 - Efficacy of an alpha-blocker for the treatment of nonneurogenic voiding dysfunction in women

T2 - An 8-week, randomized, double-blind, placebo-controlled trial

AU - Lee, Young Suk

AU - Lee, Kyu Sung

AU - Choo, Myung Soo

AU - Kim, Joon Chul

AU - Lee, Jeong Gu

AU - Seo, Ju Tae

AU - Lee, Jeong Zoo

AU - Lee, Ji Youl

AU - Oh, Seung June

AU - Na, Yong Gil

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Purpose: To evaluate the efficacy of an alpha-1 adrenergic receptor (α1-AR) blocker for the treatment of female voiding dysfunction (FVD) through a pressure-flow study. Methods: This was a randomized, double-blind, placebo-controlled trial. Women aged ≥18 years with voiding symptoms, as defined by an American Urological Association symptom score (AUA-SS) ≥15 and a maximum flow rate (Qmax) <15 mL/ sec with a voided volume of >100 mL and/or a postvoid residual (PVR) volume >150 mL, were randomly allocated to either the alfuzosin or placebo group. After 8 weeks of treatment, changes in the AUA-SS, Bristol female lower urinary tract symptoms (BFLUTS) questionnaire, Qmax/PVR, and voiding diary were compared between groups. Patients' satisfaction with the treatment was compared. Patients were categorized into 3 groups according to the Blaivas-Groutz bladder outlet obstruction (BOO) nomogram: none, mild, and moderate to severe. Subgroup comparisons were also made. Results: Of a total of 187 women, 154 (79 alfuzosin, 75 placebo) were included in the analysis. After 8 weeks of treatment, the AUA-SS decreased by 7.0 in the alfuzosin group and by 8.0 in the placebo group. Changes in AUA-SS subscores, BFLUTS (except the I-sum), the voiding diary, and Qmax/PVR were not significantly different between groups. Approximately 54% of the alfuzosin group and 62% of the placebo group were satisfied with the treatment. No significant difference was observed between groups according to the presence or grade of BOO. Conclusions: Alfuzosin might not be more effective than placebo for treating FVD. The presence or the grade of BOO did not affect the results. A further study with sufficient power is needed to determine the efficacy of α1-AR blockers for the treatment of FVD.

AB - Purpose: To evaluate the efficacy of an alpha-1 adrenergic receptor (α1-AR) blocker for the treatment of female voiding dysfunction (FVD) through a pressure-flow study. Methods: This was a randomized, double-blind, placebo-controlled trial. Women aged ≥18 years with voiding symptoms, as defined by an American Urological Association symptom score (AUA-SS) ≥15 and a maximum flow rate (Qmax) <15 mL/ sec with a voided volume of >100 mL and/or a postvoid residual (PVR) volume >150 mL, were randomly allocated to either the alfuzosin or placebo group. After 8 weeks of treatment, changes in the AUA-SS, Bristol female lower urinary tract symptoms (BFLUTS) questionnaire, Qmax/PVR, and voiding diary were compared between groups. Patients' satisfaction with the treatment was compared. Patients were categorized into 3 groups according to the Blaivas-Groutz bladder outlet obstruction (BOO) nomogram: none, mild, and moderate to severe. Subgroup comparisons were also made. Results: Of a total of 187 women, 154 (79 alfuzosin, 75 placebo) were included in the analysis. After 8 weeks of treatment, the AUA-SS decreased by 7.0 in the alfuzosin group and by 8.0 in the placebo group. Changes in AUA-SS subscores, BFLUTS (except the I-sum), the voiding diary, and Qmax/PVR were not significantly different between groups. Approximately 54% of the alfuzosin group and 62% of the placebo group were satisfied with the treatment. No significant difference was observed between groups according to the presence or grade of BOO. Conclusions: Alfuzosin might not be more effective than placebo for treating FVD. The presence or the grade of BOO did not affect the results. A further study with sufficient power is needed to determine the efficacy of α1-AR blockers for the treatment of FVD.

KW - Adrenergic alpha-antagonists

KW - Bladder outlet obstruction

KW - Female

KW - Urodynamics

UR - http://www.scopus.com/inward/record.url?scp=85046404872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046404872&partnerID=8YFLogxK

U2 - 10.5213/inj.1834904.452

DO - 10.5213/inj.1834904.452

M3 - Article

AN - SCOPUS:85046404872

VL - 22

SP - 30

EP - 40

JO - International Neurourology Journal

JF - International Neurourology Journal

SN - 2093-4777

IS - 1

ER -